Sudden Infant Death: Clinical Trials

5 completed. 5 Phase 1, 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 5
Phase 2	4	Completed 4

Follow Sudden Infant Death: new trials by email Literature Review of Sudden Infant Death trials Research Report on Sudden Infant Death

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) RGX-121 - Mucopolysaccharidosis Type II (MPS II)	Phase 1 / Phase 2	Completed	REGENXBIO Inc.	6	2021-03-11	2025-01-28
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome AGT-182 - Mucopolysaccharidosis II	Phase 1	Completed	ArmaGen, Inc	6	2015-04-01	2018-09-18
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment Idursulfase-IT, Elaprase - Hunter Syndrome	Phase 1 / Phase 2	Completed	Takeda	15	2010-08-01	2025-08-06
To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients GC1111_0.5mg/kg, GC1111_1.0mg/kg, Elaprase_0.5mg/kg - Mucopolysaccharidosis II	Phase 1 / Phase 2	Completed	Green Cross Corporation	31	2010-05-01	2012-02-14
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg) - Hunter Syndrome	Phase 1 / Phase 2	Completed	Shire	16	2009-11-18	2021-06-28

Narrower conditions

Mucopolysaccharidosis II (5)  ·  Lysosomal Storage Diseases (2)  ·  Mucopolysaccharidoses (1)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Connective Tissue Diseases (5)  ·  Death (5)  ·  Death, Sudden (5)  ·  Genetic Diseases, Inborn (5)  ·  Genetic Diseases, X-Linked (5)  ·  Heredodegenerative Disorders, Nervous System (5)  ·  Infant Death (5)  ·  Intellectual Disability (5)  ·  Metabolic Diseases (5)  ·  Metabolism, Inborn Errors (5)  ·  Mucinoses (5)  ·  Nervous System Diseases (5)  ·  Neurobehavioral Manifestations (5)

Interventions

idursulfase (1)

Sponsors

ArmaGen, Inc (1)  ·  Green Cross Corporation (1)  ·  REGENXBIO Inc. (1)  ·  Shire (1)  ·  Takeda (1)

Countries

United States (4)  ·  Canada (2)  ·  United Kingdom (2)  ·  Germany (1)  ·  Philippines (1)  ·  South Korea (1)

Top investigators

Patrice Rioux, MD PhD (1)

Results publications

PMID 23497636, PMID 35588317